159 related articles for article (PubMed ID: 23336938)
21. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA;
J Clin Oncol; 2006 Aug; 24(24):3895-903. PubMed ID: 16921040
[TBL] [Abstract][Full Text] [Related]
22. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
Lyons RM; Cosgriff TM; Modi SS; Gersh RH; Hainsworth JD; Cohn AL; McIntyre HJ; Fernando IJ; Backstrom JT; Beach CL
J Clin Oncol; 2009 Apr; 27(11):1850-6. PubMed ID: 19255328
[TBL] [Abstract][Full Text] [Related]
23. Azacitidine adverse effects in patients with myelodysplastic syndromes.
San Miguel Amigo L; Franco Osorio R; Mercadal Vilchez S; Martínez-Francés A
Adv Ther; 2011 Jun; 28 Suppl 4():6-11. PubMed ID: 21688207
[TBL] [Abstract][Full Text] [Related]
24. Adverse effects of azacitidine: onset, duration, and treatment.
Martínez-Francés A
Adv Ther; 2011 Jun; 28 Suppl 4():1-5. PubMed ID: 21688206
[TBL] [Abstract][Full Text] [Related]
25. 5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.
Breccia M; Salaroli A; Loglisci G; Martelli M; D'Elia GM; Nanni M; Mauro FR; Alimena G
Leuk Res; 2011 Oct; 35(10):1409-11. PubMed ID: 21680017
[TBL] [Abstract][Full Text] [Related]
26. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R;
Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554
[TBL] [Abstract][Full Text] [Related]
27. Interstitial lung disease associated with azacitidine use: a case report.
Sekhri A; Palaniswamy C; Kurmayagari K; Kalra A; Selvaraj DR
Am J Ther; 2012 Mar; 19(2):e98-e100. PubMed ID: 20634671
[TBL] [Abstract][Full Text] [Related]
28. Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review.
Thorpe M; Montalvão A; Pierdomenico F; Moita F; Almeida A
Leuk Res; 2012 Aug; 36(8):1071-3. PubMed ID: 22607959
[TBL] [Abstract][Full Text] [Related]
29. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.
Fenaux P; Ades L
Leuk Res; 2009 Dec; 33 Suppl 2():S7-11. PubMed ID: 20004796
[TBL] [Abstract][Full Text] [Related]
30. A limited number of 5-azacitidine cycles can be effective treatment in MDS.
Müller-Thomas C; Schuster T; Peschel C; Götze KS
Ann Hematol; 2009 Mar; 88(3):213-9. PubMed ID: 18696067
[TBL] [Abstract][Full Text] [Related]
31. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection.
Issa JP
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S24-9. PubMed ID: 16341237
[TBL] [Abstract][Full Text] [Related]
32. Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept.
Scott BL; Ramakrishnan A; Storer B; Becker PS; Petersdorf S; Estey EH; Deeg HJ
Br J Haematol; 2010 Mar; 148(6):944-7. PubMed ID: 20064151
[TBL] [Abstract][Full Text] [Related]
33. Acute myeloblastic leukemia.
Molina CA; Rodríguez MJ; de Marcos NS; Font P
Adv Ther; 2011 Mar; 28 Suppl 3():10-6. PubMed ID: 21431629
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).
Wijermans PW; Rüter B; Baer MR; Slack JL; Saba HI; Lübbert M
Leuk Res; 2008 Apr; 32(4):587-91. PubMed ID: 17881052
[TBL] [Abstract][Full Text] [Related]
35. Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program.
Maurillo L; Venditti A; Spagnoli A; Gaidano G; Ferrero D; Oliva E; Lunghi M; D'Arco AM; Levis A; Pastore D; Di Renzo N; Santagostino A; Pavone V; Buccisano F; Musto P
Cancer; 2012 Feb; 118(4):1014-22. PubMed ID: 21761399
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of azacitidine in myelodysplastic syndromes.
Vigil CE; Martin-Santos T; Garcia-Manero G
Drug Des Devel Ther; 2010 Sep; 4():221-9. PubMed ID: 20957213
[TBL] [Abstract][Full Text] [Related]
37. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
Aribi A; Borthakur G; Ravandi F; Shan J; Davisson J; Cortes J; Kantarjian H
Cancer; 2007 Feb; 109(4):713-7. PubMed ID: 17219444
[TBL] [Abstract][Full Text] [Related]
38. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Beran M; Kantarjian H
Semin Hematol; 1999 Oct; 36(4 Suppl 8):3-10. PubMed ID: 10622223
[TBL] [Abstract][Full Text] [Related]
39. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency.
Batty GN; Kantarjian H; Issa JP; Jabbour E; Santos FP; McCue D; Garcia-Manero G; Pierce S; O'Brien S; Cortés JE; Ravandi F
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):205-10. PubMed ID: 20511166
[TBL] [Abstract][Full Text] [Related]
40. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine.
Adès L; Sekeres MA; Wolfromm A; Teichman ML; Tiu RV; Itzykson R; Maciejewski JP; Dreyfus F; List AF; Fenaux P; Komrokji RS
Leuk Res; 2013 Jun; 37(6):609-13. PubMed ID: 23415110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
